L. , Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

D. Sur,

. Diabète,

D. Sur,

, REMICADE® (infliximab) : modification des indications et renforcement des contre-indications et mises en gardes -ANSM : Agence nationale de sécurité du médicament et des produits de santé

H. Cohen, D. Beydoun, D. Chien, T. Lessor, D. Mccabe et al., Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians, Adv Ther, vol.33, issue.12, pp.2160-72, 2016.

J. Sieczkowska-golub, D. Jarzebicka, G. Oracz, and J. Kierkus, Biosimilars in paediatric inflammatory bowel disease, World J Gastroenterol. 21 sept, vol.24, issue.35, pp.4021-4028, 2018.

, Directive 2001/83/CE du Parlement européen et du Conseil du 6 novembre, 2001.

, DELIBERATION n°2012-269 du 19 juillet, 2012.

, -1203 du 22 décembre 2018 de financement de la sécurité sociale pour 2019, 1203.

, Biosimilars in the EU -Information guide for healthcare professionals -now available in 23 languages [Internet]. Medicines for Europe, 2019.

D. Sur, Pharmaceutical evaluation of biosimilars: Important differences from generic low-molecularweight pharmaceuticals | Request PDF

. Researchgate,

M. Nowicki, Basic facts about biosimilars, Kidney Blood Press Res, vol.30, issue.5, pp.267-72, 2007.

S. D. Roger, Biosimilars: how similar or dissimilar are they? Nephrol Carlton Vic, août, vol.11, issue.4, pp.341-347, 2006.

I. , Culture cellulaire : Trois étapes clés pour produire des protéines thérapeutiques. 1 avr, 2011.

, Disponible sur: /culture-cellulaire-trois-etapes-cles-pour-produire-desproteines-therapeutiques, p.39248

, Apport des biosimilaires et des nouvelles biothérapies dans le traitement des maladies inflammatoires chroniques de l'intestin

. Fmc-hge,

D. Sur,

, Introduction à laBiotechnologie

. Issuu,

D. Sur,

. Biosimilaires-|-amgen,

I. Amgen,

D. Sur,

J. Altman, C. N. Delemer, B. Travert, F. Benabbad, and I. , Développement des biosimilaires de l'insuline : exemple de l'insuline glargine LY2963016. Presse Médicale, vol.47, pp.854-66, 2018.

, Comités européens pour l'évaluation et la surveillance des médicaments -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

D. Sur,

, Médicaments sous surveillance renforcée -ANSM : Agence nationale de sécurité du médicament et des produits de santé

É. Nouguez, Chapitre 1. Aux origines du marché français des médicaments génériques, Academique. 7 déc, pp.25-42, 2017.

, European public assessment reports: background and context

, European Medicines Agency, 2018.

C. K. Schneider, Biosimilars in rheumatology: the wind of change, Ann Rheum Dis. 1 mars, vol.72, issue.3, pp.315-323, 2013.

, Biosimilar medicines: Overview | European Medicines Agency

D. Sur,

G. F. Schimizzi, Biosimilars from a practicing rheumatologist perspective: An overview, Autoimmun Rev. sept, vol.15, issue.9, pp.911-917, 2016.

M. Biosimilaires,

. Medicines,

A. European-medicines,

D. Sur,

, EMA approves adalimumab and pegfilgrastim biosimilars / News / Biosimilars / Home -GaBI Online -Generics and Biosimilars Initiative

, Les biosimilaires en 15 questions

, Le Quotidien du Pharmacien.fr

D. Sur,

J. O'callaghan, M. Bermingham, M. Leonard, F. Hallinan, J. M. Morris et al., Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland, Regul Toxicol Pharmacol. 1 août, vol.88, pp.252-61, 2017.

B. Bressler and T. Dingermann, Establishing a new marketplace for biologic therapy with biosimilar agents: importance of extrapolation of data

, Biosimilars, vol.5, pp.41-49, 2015.

R. Stanhope, F. Sörgel, P. Gravel, P. Schuetz, Y. B. Zabransky et al., Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis, J Clin Pharmacol, vol.50, issue.11, pp.1339-1387, 2010.

, Le bon usage du médicament et des thérapeutiques non médicamenteuses, vol.10

H. Autorité-de-santé,

G. Cancarini, Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council, Nephrol Dial Transplant

D. Sur,

, Les médicaments génériques et biosimilaires, 2019.

B. Calvo, J. Martinez-gorostiaga, and E. Echevarria, The surge in biosimilars: considerations for effective pharmacovigilance and EU regulation, Ther Adv Drug Saf. oct, vol.9, issue.10, pp.601-609, 2018.

, Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on Biosimilars -PubMed

P. Kurki, L. Van-aerts, E. Wolff-holz, T. Giezen, V. Skibeli et al., Interchangeability of Biosimilars: A European Perspective, BioDrugs Clin Immunother Biopharm Gene Ther. avr, vol.31, issue.2, pp.83-91, 2017.

A. S. Tsiftsoglou, S. Ruiz, and C. K. Schneider, Development and regulation of biosimilars: current status and future challenges, BioDrugs Clin Immunother Biopharm Gene Ther. juin, vol.27, issue.3, pp.203-214, 2013.

, La commission de la transparence précise et adapte ses principes d'évaluation des médicaments

H. Autorité-de-santé,

W. Reinisch and J. Smolen, Biosimilar safety factors in clinical practice, Semin Arthritis Rheum. juin, vol.44, issue.6, pp.9-15, 2015.

C. Research, Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. FDA [Internet, vol.8

D. Sur,

, Décret n° 2016-960 du 12 juillet 2016 relatif à l'inscription des médicaments biologiques similaires sur la liste de référence des groupes biologiques similaires, 2016.

M. Bonafede, G. J. Joseph, N. Princic, and D. J. Harrison, Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis, J Med Econ. sept, vol.16, issue.9, pp.1120-1128, 2013.

K. Laas, R. Peltomaa, H. Kautiainen, K. Puolakka, and M. Leirisalo-repo, Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment, Ann Rheum Dis. juill, vol.65, issue.7, pp.924-932, 2006.

A. Lehmann, M. Baudrant-boga, P. Bedouch, M. Robein-dobremez, B. Allenet et al., Optimisation de la dispensation des médicaments hospitaliers aux patients ambulatoires, J Pharm Clin. 1 avr, vol.28, issue.2, pp.89-96, 2009.

, Les biomédicaments et les médicaments biosimilaires

. Biogaran,

D. Sur, Biosimilaires : une voie complexe mais prometteuse

, Revue Pharma, 2019.

D. Sur,

, La rémunération sur objectifs de Santé Publique en 2018-Bilan à un an du nouveau dispositif, Dossier de presse 25 avril 2018 -Recherche Google

D. Sur, %A9+Publique+en+2018-Bilan+%C3%A0+un+an+du+nouveau+dispositif%2C+Dossier+de+presse+25+avril+2018&oq=La+r %C3%A9mun%C3%A9ration+sur+objectifs+de+Sant%C3%A9+Publique+en+2018-Bilan+%C3%A0+un+an+du+nouveau+dispositif%2C+Dossier+de+presse+25+avril+2018&aqs=chro me..69i57, pp.448-448

D. Pinheiro, Bilan en 2012 sur l'utilisation des biosimilaires -Recherche Google

D. Sur,

, What you Need to Know About Biosimilar Medicinal Products [Internet]. Medicines for Europe, 2015.

J. G. Stevenson, R. Popovian, I. Jacobs, S. Hurst, and L. G. Shane, Biosimilars: Practical Considerations for Pharmacists, Ann Pharmacother. juill, vol.51, issue.7, pp.590-602, 2017.

. Portela-m-da-cc, C. Sinogas, A. De-almeida, F. Baptista-leite, R. Castro-caldas et al., Biologicals and biosimilars: safety issues in Europe, Expert Opin Biol Ther, vol.17, issue.7, pp.871-878, 2017.

, -1203 du 23 décembre 2013 de financement de la sécurité sociale pour 2014, 1203.

, Les médicaments biosimilaires -ANSM : Agence nationale de sécurité du médicament et des produits de santé

, -1827 du 23 décembre 2016 de financement de la sécurité sociale pour 2017, 1827.

, ANSM publie un état des lieux sur les médicaments biosimilaires -Point d'information -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur, Biosimilaires : la loi de financement de la Sécurité sociale pour 2020 supprime le droit de substitution -Communications -Ordre National des Pharmaciens

D. Sur,

A. Stats,

D. Sur, Contrat d'Amélioration de la Qualité et de l'Efficience des Soins (CAQES)

D. Sur,

, Nos Analyses

. Gers,

D. Sur,

S. Danese, G. Fiorino, and P. Michetti, Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization, J Crohns Colitis, vol.8, issue.11, pp.1548-50, 2014.

, Pan-European survey calls for a shift in policy for biosimilars

. Europabio,

R. O. Dolinar and M. S. Reilly, Biosimilars naming, label transparency and authority of choice -survey findings among European physicians, Generics Biosimilars Initiat J. 15 juin, vol.3, issue.2, pp.58-62, 2014.

A. Hallersten, W. Fürst, and R. Mezzasalma, Physicians prefer greater detail in the biosimilar label (SmPC) -Results of a survey across seven European countries, Regul Toxicol Pharmacol RTP. juin, vol.77, pp.275-81, 2016.

D. Grabowski, B. Henderson, D. Lam, E. C. Keystone, C. Thorne et al., Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists, Clin Rheumatol. août, vol.34, issue.8, pp.1427-1460, 2015.

M. Beck, B. Michel, R. Levêque, D. Sordet, C. Sibilia et al., Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey, BioDrugs. 1 déc, vol.30, issue.6, pp.585-92, 2016.

, ASBM-Survey-1.pdf

D. Sur,

L. Frantzen, J. Cohen, S. Tropé, M. Beck, A. Munos et al., Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey, Joint Bone Spine, vol.86, issue.4, pp.491-497, 2019.

L. Peyrin-biroulet, S. Lönnfors, X. Roblin, S. Danese, and L. Avedano, Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations, J Crohns Colitis. janv, vol.11, issue.1, pp.128-161, 2017.

A. Teeple, L. A. Ellis, L. Huff, C. Reynolds, S. Ginsburg et al., Physician attitudes about nonmedical switching to biosimilars: results from an online physician survey in the United States, Curr Med Res Opin, vol.35, issue.4, pp.611-618, 2019.

I. Paw?owska, L. Paw?owski, N. Krzy?aniak, and I. Koci?, Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals, BioDrugs Clin Immunother Biopharm Gene Ther. avr, vol.33, issue.2, pp.183-91, 2019.

K. Tanabe, N. Sugimoto, and Y. Fujimoto, A Web-Based Survey to Investigate the Extent of Awareness and Understanding for Biosimilar among Japanese Physicians and Pharmacists. Value Health, vol.18, p.658, 2015.

, Latin American Physicians Support Distinguishable Biosimilar Naming, Survey Finds -Safe Biologics

A. Adé, O. Bourdon, and J. Bussières, A survey of pharmacists' knowledge and views of biosimilars in Quebec and France, Ann Pharm Fr. juill, vol.75, issue.4, pp.267-75, 2017.

, NACCME Releases Results of Survey Assessing Medical Education Needs in Biosimilars

. Prweb,

L. Pasina, G. Casadei, and A. Nobili, A survey among hospital specialists and pharmacists about biosimilars, Eur J Intern Med. nov, vol.35, pp.31-34, 2016.

F. Farhat, A. Othman, F. El-karak, and J. Kattan, Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region. SpringerPlus [Internet]. 30 déc, Disponible sur, vol.5, 2016.

M. Weise, M. Bielsky, D. Smet, K. Ehmann, F. Ekman et al., Biosimilars: what clinicians should know, Blood. 20 déc, vol.120, issue.26, pp.5111-5118, 2012.

M. Weise, P. Kurki, E. Wolff-holz, M. Bielsky, and C. K. Schneider, Biosimilars: the science of extrapolation, Blood, vol.124, issue.22, pp.3191-3197, 2014.

E. Leonard, M. Wascovich, S. Oskouei, P. Gurz, and D. Carpenter, Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review, J Manag Care Spec Pharm. janv, vol.25, issue.1, pp.102-114, 2019.

, Roundtable on biosimilars with European regulators and medical societies, 2016.

F. De-mora, Biosimilar: what it is not, Br J Clin Pharmacol, vol.80, issue.5, pp.949-56, 2015.

, Pour une utilisation en confiance du médicament biosimilaire : création d'un support d'information aux Hospices Civils de Lyon, 2019.

H. Mellstedt, D. Niederwieser, and H. Ludwig, The challenge of biosimilars, Ann Oncol Off J Eur Soc Med Oncol. mars, vol.19, issue.3, pp.411-420, 2008.

M. Beck, B. Michel, R. Sordet, C. Sibilia, J. Velten et al., Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?, Eur J Hosp Pharm. mars, vol.24, issue.2, pp.85-90, 2017.

P. Mcgettigan, J. Mcmanus, O. Shea, B. Chan, R. Feely et al., Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: prescribers' concerns, Ir Med J. juill, vol.90, issue.4, pp.146-153, 1997.

S. S. Dunne, B. Shannon, W. Cullen, and C. P. Dunne, Beliefs, perceptions and behaviours of GPs towards generic medicines, Fam Pract. août, vol.31, issue.4, pp.467-74, 2014.

A. O'leary, C. Usher, M. Lynch, M. Hall, L. Hemeryk et al., Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland, BMC Res Notes. 15 déc, vol.8, p.790, 2015.

. Anonymous and . Inflectra,

, European Medicines Agency, 2018.

. Anonymous and . Remsima,

, European Medicines Agency, 2018.

W. Park, P. Hrycaj, S. Jeka, V. Kovalenko, G. Lysenko et al., A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study, Ann Rheum Dis, vol.72, issue.10, pp.1605-1617, 2013.

D. H. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski et al., A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Ann Rheum Dis, vol.72, issue.10, pp.1613-1633, 2013.

, The NOR-SWITCH Study -Full Text View -ClinicalTrials.gov

D. Sur,

E. Nikiphorou, H. Kautiainen, P. Hannonen, J. Asikainen, A. Kokko et al., Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data, Expert Opin Biol Ther, vol.15, issue.12, pp.1677-83, 2015.

J. Sieczkowska, D. Jarz?bicka, A. Banaszkiewicz, A. Plocek, A. Gawronska et al., Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations, J Crohns Colitis. févr, vol.10, issue.2, pp.127-159, 2016.

. Efficacy, . Ct-p13, and . Infliximab, patients with inflammatory bowel disease: A retrospective multicenter study -Jung -2015 -Journal of Gastroenterology and Hepatology -Wiley Online Library

, « Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial » -Full Text View -ClinicalTrials.gov [Internet

, Full article: Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea, vol.106

. Bio-switch and . Study, Biosimilar of Infliximab Options, Strengths and Weaknesses of Infliximab Treatment CHange -AdisInsight

J. Braun and A. Kudrin, Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases, Immunotherapy, vol.7, issue.2, pp.73-87, 2015.

J. Kay, B. G. Feagan, M. S. Guirguis, E. C. Keystone, A. V. Klein et al., Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Biol -Lond, vol.40, issue.6, pp.517-544, 2012.

T. Dörner, V. Strand, G. Castañeda-hernández, G. Ferraccioli, J. D. Isaacs et al., The role of biosimilars in the treatment of rheumatic diseases, Ann Rheum Dis. mars, vol.72, issue.3, pp.322-330, 2013.

A. Inotai, M. Csanadi, G. Petrova, M. Dimitrova, T. Bochenek et al., Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts, Unmet Medical Need, p.9597362, 2018.

N. S. Vermeer, S. Straus, A. K. Mantel-teeuwisse, F. Domergue, T. Egberts et al., Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases, Drug Saf. août, vol.36, issue.8, pp.617-642, 2013.

K. Klein, J. Scholl, N. S. Vermeer, A. W. Broekmans, E. P. Van-puijenbroek et al., Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports, Drug Saf. févr, vol.39, issue.2, pp.185-92, 2016.

C. P. Underhill, Biosimilars and inflammatory bowel disease: a switch programme using CT-P13, Pharmaceutical Journal

, Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, p.13

R. Thorpe, Terminology for biosimilars-a confusing minefield, Generics Biosimilars Initiat J. 15 août, vol.1, issue.3-4, pp.132-136, 2012.

E. A. Alexander, The biosimilar name debate: what's at stake for public health, Generics Biosimilars Initiat J. 15 mars, vol.3, issue.1, pp.10-12, 2014.

, Factors Affecting Physician Professional Satisfaction and Their Implications for Patient Care, Health Systems, and Health Policy | RAND

C. P. West, L. N. Dyrbye, and T. D. Shanafelt, Physician burnout: contributors, consequences and solutions, J Intern Med, vol.283, issue.6, pp.516-545, 2018.

, Officer (CTO) O of the CT. CMS Physician Engagement and Burden Reduction Initiative

. Hhs and . Gov, , 2018.

J. Waller, E. Sullivan, J. Piercy, C. M. Black, and S. Kachroo, Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany, Patient Prefer Adherence, vol.11, pp.519-549, 2017.

M. Scherlinger, E. Langlois, V. Germain, and T. Schaeverbeke, Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4), Semin Arthritis Rheum, vol.48, issue.5, pp.927-959, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01992911

G. L. Goll, E. A. Haavardsholm, and T. K. Kvien, The confidence of rheumatologists about switching to biosimilars for their patients, Joint Bone Spine, vol.85, issue.5, pp.507-516, 2018.

J. Sigaux, L. Semerano, and M. Boissier, Switch to a biosimilar: Whatever the cost?, Joint Bone Spine, vol.85, issue.6, pp.651-655, 2018.

A. Barsell, M. Rengifo-pardo, and A. Ehrlich, A Survey Assessment of US Dermatologists' Perception of Biosimilars, J Drugs Dermatol JDD. 1 juin, vol.16, issue.6, pp.612-617, 2017.

A. Teeple, S. Ginsburg, L. Howard, L. Huff, C. Reynolds et al., Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States, Curr Med Res Opin, vol.35, issue.4, pp.603-612, 2019.

F. Wolfe and K. Michaud, Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices, Arthritis Rheum. juill, vol.56, issue.7, pp.2135-2177, 2007.

S. S. Dunne, What Do Users of Generic Medicines Think of Them? A Systematic Review of Consumers' and Patients' Perceptions of, and Experiences with, Generic Medicines. The Patient, vol.9, issue.6, pp.499-510, 2016.

J. Avouac, A. Moltó, V. Abitbol, A. Etcheto, A. Salcion et al., Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Semin Arthritis Rheum, vol.47, issue.5, pp.741-749, 2018.

N. W. Boone, L. Liu, M. J. Romberg-camps, L. Duijsens, C. Houwen et al., The nocebo effect challenges the non-medical infliximab switch in practice, Eur J Clin Pharmacol. mai, vol.74, issue.5, pp.655-61, 2018.

M. F. Rezk and B. Pieper, Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect, Rheumatol Ther. déc, vol.4, issue.2, pp.209-227, 2017.

, Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: An Updated Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines

. Ottawa, Canadian Agency for Drugs and Technologies in Health, CADTH Rapid Response Reports). Disponible sur, 2017.

T. Schaeverbeke, T. Pham, C. Richez, and D. Wendling, Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI), Joint Bone Spine, vol.85, issue.4, pp.399-402, 2018.

R. A. Colbert and B. N. Cronstein, Biosimilars: the debate continues, Arthritis Rheum, vol.63, issue.10, pp.2848-50, 2011.

C. Mccall, Biosimilars for insulin: a cost-saving alternative?, Lancet Lond Engl, vol.11, pp.463-467, 2018.

E. A. Blackstone and P. F. Joseph, The economics of biosimilars, Am Health Drug Benefits. sept, vol.6, issue.8, pp.469-78, 2013.

R. Haustein, C. De-millas, A. Höer, and P. B. Häussler, Saving money in the European healthcare systems with biosimilars, Generics Biosimilars Initiat J, vol.7, 2012.

, Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis

, ACR Meeting Abstracts

D. Sur,

. Ims and . Health, Surge in Biosimilars to Drive Significant Change in Health System Costs, Patient Access and Competition by 2020 | Business Wire

A. Hemmington, N. Dalbeth, P. Jarrett, A. G. Fraser, R. Broom et al., Medical specialists' attitudes to prescribing biosimilars, Pharmacoepidemiol Drug Saf. mai, vol.26, issue.5, pp.570-577, 2017.

, Prescribing Practices and Usage of Generics | ESRI, Pharmaceutical Prices

. Ims-health-report, The Impact of Biosimilar Competition" is Released, 2016.

, Medicine Management Programme

. Hse,

D. Sur,

, BSG guidance recommends switching to biosimilar infliximab -GaBI Journal, 2016.

. Rcp-london, , 2016.

A. W. Mulcahy, Z. Predmore, and S. Mattke, The Cost Savings Potential of Biosimilar Drugs in the United States, p.16

R. Fleischmann and . Editorial, The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and Black, Arthritis Rheumatol Hoboken NJ, vol.70, issue.3, pp.323-328, 2018.

A. Inotai, C. Prins, M. Csanádi, D. Vitezic, C. Codreanu et al., Is there a reason for concern or is it just hype? -A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars, Expert Opin Biol Ther, vol.17, issue.8, pp.915-941, 2017.

, Ruptures d'approvisionnement et DP-Ruptures -Le Dossier Pharmaceutique -Ordre National des Pharmaciens

, Nonmedical switching

U. S. , Pain Foundation

D. Sur,

. H-125, 991 Drug Formularies and Therapeutic Interchange | AMA

B. F. Banahan and E. M. Kolassa, A physician survey on generic drugs and substitution of critical dose medications, Arch Intern Med, vol.157, issue.18, pp.2080-2088, 1997.

C. Mendoza, D. Ionescu, G. Radière, C. Rémuzat, K. E. Young et al., Biosimilar Substitution Policies: An Overview. Value Health, vol.18, p.525, 2015.

F. Bocquet and P. Paubel, First monoclonal antibody biosimilars: tackling the challenge of substitution, J Med Econ. juin, vol.19, issue.6, pp.645-652, 2016.

K. K. Jørgensen, I. C. Olsen, G. L. Goll, M. Lorentzen, N. Bolstad et al., Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial, Lancet Lond Engl, vol.10, pp.2304-2320, 2017.

Y. Sung, S. Cho, D. Kim, S. Won, C. Choi et al., Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab, Rheumatol Int. juin, vol.37, issue.6, pp.1007-1021, 2017.

S. M. Devlin, B. Bressler, C. N. Bernstein, R. N. Fedorak, A. Bitton et al., Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics, Can J Gastroenterol J Can Gastroenterol, vol.27, issue.10, pp.567-71, 2013.

, Canadian Dermatology Association

D. Sur,

H. Canada, Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs, 2016.

. Anonymous, Similar biological medicinal products

, European Medicines Agency, 2018.

, Meetings on User Fee Program for Biosimilar and Interchangeable Biological Product Applications; Request for Notification of Stakeholder Intention To Participate, Biologics Price Competition and Innovation Act, 2009.

D. Sur,

E. Van-overbeeke, D. Beleyr, B. De-hoon, J. Westhovens, R. Huys et al., Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists, BioDrugs Clin Immunother Biopharm Gene Ther, vol.31, issue.5, pp.447-59, 2017.

, Pharmacy-mediated substitution of biosimilars -a global survey benchmarking country substitution policies -GaBI Journal

A. L. Benedict, State-level legislation on follow-on biologic substitution, J Law Biosci. 1 juin, vol.1, issue.2, pp.190-201, 2014.

A. S. Russell, V. Ahluwalla, C. Barnabe, S. Jamal, R. C. Offer et al., Subsequent entry biologics/biosimilars: a viewpoint from Canada, Clin Rheumatol. sept, vol.31, issue.9, pp.1289-92, 2012.

V. Brodszky, P. Baji, O. Balogh, and M. Péntek, Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries, Eur J Health Econ HEPAC Health Econ Prev Care. mai, vol.15, issue.1, pp.65-71, 2014.

A. Jha, A. Upton, W. Dunlop, and R. Akehurst, The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries, Adv Ther. 1 août, vol.32, issue.8, pp.742-56, 2015.

, Physicians' opinions on generic antiretroviral drugs and single-tablet regimen desimplification for the treatment of HIV infection: a multicentre survey in Spain -PubMed

, VIDAL -ZARZIO 30 MU/0,5 ml sol inj/p perf en ser préremplie -Pharmacodynamie

S. Danese, G. Fiorino, and P. Michetti, Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey, J Crohns Colitis, vol.10, issue.11, pp.1362-1367, 2016.

, Prescription de biosimilaires : à l'hôpital, une ROSP expérimentale pour les services bons élèves | Le Quotidien du médecin

, Une expérimentation pour augmenter la prescription de biosimilaires -Communications -Ordre National des Pharmaciens

, Arrêté du 3 août 2018 relatif à l'expérimentation pour l'incitation à la prescription hospitalière de médicaments biologiques similaires délivrés en ville

, 26 mars 2019 relative à l'incitation à la prescription hospitalière de médicaments biologiques similaires, lorsqu'ils sont délivrés en ville

B. Haraoui, W. Bensen, L. Bessette, L. Clercq, S. Thorne et al., Treating rheumatoid arthritis to target: a Canadian physician survey, J Rheumatol. mai, vol.39, issue.5, pp.949-53, 2012.

, Methods of coping with social desirability bias: A review -Nederhof -1985, European Journal of Social Psychology

D. Sur,